Residual cancer burden and non-pCR are associated with an increased risk of disease recurrence [7], and achievement of pCR after neoadjuvant therapy may be prognostic as it appears to be a reasonable surrogate marker of long-term outcomes in patients with HER2+ BC [19]. This evidence concerns the gene ERBB2 and breast cancer.